Input of C11-Choline PET/CT in Localization of Parathyroid Adenoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01221896|
Recruitment Status : Unknown
Verified October 2010 by Hadassah Medical Organization.
Recruitment status was: Not yet recruiting
First Posted : October 15, 2010
Last Update Posted : October 15, 2010
The purpose of the study is to determine a possible input of C11-Choline PET/CT in identification and localization of a parathyroid adenoma (PTA).
Preoperative localization of a PTA has been previously documented in multiple series, and is usually based on scintigraphy and on US.
Currently, the conventional technique for localization of a PTA is a dual-isotope scan with Tc99m-MIBI and Tc99m pertechnetate. This study is acquired over at least 3 hours, includes two i.v. injections and the patient has to stay 15-30 min per acquisition under the camera.
In addition, there is no anatomical imaging and further correlation with US is usually recommended.
In contrast, PET/CT study with C11-Choline takes as long as 10 min., includes one injection, and provides data of higher resolution of functional (PET) and anatomical imaging (CT).
Furthermore, dosimetric data shows that the total effective dose from Tc99mMIBI and Tc99m pertechnetate injection is (without CT): 0.5957 rem; and from C11-Choline injection and CT of a chest is: 0.3128 - 0.8628rem.
|Condition or disease||Intervention/treatment|
|Hyperparathyroidism||Procedure: C11-Choline PET/CT|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||January 2014|
Patients with hyperparathyroidism, prior to surgery.
Procedure: C11-Choline PET/CT
- Improved localization of a parathyroid adenoma
- Facilitation of detection of the parathyroid adenoma at surgery
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01221896
|Contact: Marina Orevi, MDemail@example.com|
|Hadassah Hebrew University Medical Center||Not yet recruiting|
|Jerusalem, Israel, 91120|
|Contact: Marina Orevi, MD 0508946211 firstname.lastname@example.org|